WuXi XDC’s DP3 Facility at Wuxi Site Gains GMP Approval, Expands Manufacturing Capacity
Tuesday, August 05, 2025
WuXi XDC has announced the GMP release of its newly launched Drug Product 3 (DP3) facility at the Wuxi site, completed at the end of July 2025.
The milestone marks a significant step in the company’s ongoing efforts to expand its drug product manufacturing capabilities within the bioconjugate sector.
The DP3 facility was designed, constructed, and brought online in just 18 months, covering all essential stages including equipment qualification, media fill, and regulatory inspection. With this addition, the combined annual manufacturing capacity of the company’s three drug product facilities at the Wuxi site—DP1, DP2, and DP3—now stands at around 15 million vials, with DP3 alone expected to handle up to 7 million vials per year.
Built to international standards, the DP3 facility is equipped with high-potency and sterile processing systems, single-use technologies, and a comprehensive environmental monitoring system. It supports the production of both liquid and lyophilised sterile products, offering services from clinical to commercial-scale manufacturing.
The facility complies with GMP guidelines from regulatory bodies including the US FDA, EMA, and NMPA. It integrates multiple stages of the production process—ranging from material disinfection, formulation, filling, and lyophilisation, to visual inspection and final packaging.
Key features include high-speed vial filling of up to 300 vials per minute, automated weight checks, non-vacuum stoppering, and a dual-camera system to detect stopper alignment. A fully automated packaging line manages labelling, carton packing, end-of-line processing, and ensures full product traceability.
The launch of DP3 is part of WuXi XDC’s broader strategy to expand its global manufacturing network, reinforcing its role as a key partner in the development and production of bioconjugates.
Source: wuxixdc.com
